Can you provide the average price target for VERACYTE INC stock?
19 analysts have analysed VCYT and the average price target is 50.17 USD. This implies a price increase of 52.99% is expected in the next year compared to the current price of 32.79.
NASDAQ:VCYT • US92337F1075
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VERACYTE INC (VCYT).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-06 | Morgan Stanley | Maintains | Underweight -> Underweight |
| 2026-02-26 | Needham | Maintains | Buy -> Buy |
| 2026-01-05 | Guggenheim | Maintains | Buy -> Buy |
| 2025-12-02 | Morgan Stanley | Maintains | Underweight -> Underweight |
| 2025-11-11 | Morgan Stanley | Maintains | Underweight -> Underweight |
| 2025-11-05 | Guggenheim | Maintains | Buy -> Buy |
| 2025-11-05 | UBS | Maintains | Buy -> Buy |
| 2025-11-05 | Needham | Maintains | Buy -> Buy |
| 2025-11-05 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2025-10-20 | Canaccord Genuity | Initiate | Hold |
| 2025-10-17 | Freedom Capital Markets | Initiate | Buy |
| 2025-05-08 | UBS | Maintains | Buy -> Buy |
| 2025-05-08 | Needham | Maintains | Buy -> Buy |
| 2025-04-09 | Guggenheim | Maintains | Buy -> Buy |
| 2025-03-26 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-03-20 | Craig-Hallum | Initiate | Buy |
| 2025-02-25 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-02-25 | UBS | Maintains | Buy -> Buy |
| 2025-02-25 | Needham | Reiterate | Buy -> Buy |
| 2025-01-29 | Needham | Maintains | Buy -> Buy |
| 2024-12-05 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2024-11-18 | Morgan Stanley | Maintains | Underweight -> Underweight |
| 2024-11-08 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2024-11-07 | UBS | Maintains | Buy -> Buy |
| 2024-11-07 | Needham | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 361.051M 21.77% | 445.764M 23.46% | 517.145M 16.01% | 586.86M 13.48% | 661.19M 12.67% | 729.22M 10.29% | 799.58M 9.65% | 866.59M 8.38% | 950.95M 9.73% | |
| EBITDA YoY % growth | 9.742M 182.07% | 42.969M 341.07% | 99.697M 132.02% | 147.12M 47.57% | 170.87M 16.14% | 193.15M 13.04% | 213.11M 10.33% | 236.57M 11.01% | 274.18M 15.90% | |
| EBIT YoY % growth | -17.446M 53.85% | 19.51M 211.83% | 78.282M 301.24% | 78.084M -0.25% | 105.15M 34.66% | 141.11M 34.20% | 126.43M -10.40% | 148.05M 17.10% | 195.23M 31.87% | |
| Operating Margin | -4.83% | 4.38% | 15.14% | 13.31% | 15.90% | 19.35% | 15.81% | 17.08% | 20.53% | |
| EPS YoY % growth | -1.03 -106.00% | 0.30 129.13% | 0.83 176.67% | 1.16 39.38% | 1.34 15.63% | 1.67 25.21% | 2.07 23.43% | 2.17 5.10% | 2.32 6.57% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.15 71.42% | 0.29 2,999.76% | 0.32 33.88% | 0.32 -37.00% | 0.39 151.24% | 0.47 61.81% | 0.49 52.38% | 0.50 55.56% |
| Revenue Q2Q % growth | 133.22M 16.38% | 146.75M 12.74% | 148.07M 12.28% | 152.53M 8.46% | 139.81M 4.95% | 155.57M 6.01% | 160.04M 8.08% | 168.25M 10.31% |
| EBITDA Q2Q % growth | 29.805M 260.57% | 36.865M 41.31% | 38.773M -0.74% | 40.386M -31.09% | 30.07M 0.89% | 39.596M 7.41% | 41.035M 5.83% | 45.543M 12.77% |
| EBIT Q2Q % growth | 15.556M 435.67% | 21.821M 43.21% | 21.909M -4.52% | 22.895M -38.45% | 28.244M 81.56% | 37.801M 73.23% | 39.209M 78.96% | 43.748M 91.08% |
All data in USD
19 analysts have analysed VCYT and the average price target is 50.17 USD. This implies a price increase of 52.99% is expected in the next year compared to the current price of 32.79.
VERACYTE INC (VCYT) will report earnings on 2026-05-05, after the market close.
The consensus EPS estimate for the next earnings of VERACYTE INC (VCYT) is 0.15 USD and the consensus revenue estimate is 133.22M USD.
The number of analysts covering VERACYTE INC (VCYT) is 19.